AUD vs USD – Which Currency Should You Bank On?

By MoneyMorning.com.au

The letter below came from a Gowdie Family Wealth reader recently. Since the answer has a lot to do with my current strategy for Aussie investors, I thought I’d answer it here.

Hi Vern,

I’ve been wondering about the parlous state of the US economy – if/when it goes kaput will the Aussie $ strengthen against the greenback?

Ray

Hello Ray!

Good question.

With the debt ceiling issued now settled (at least until Feb 2014) things will continue as before – more excessive spending financed by the Fed’s $85 billion per month asset purchases.

Yes the US is in a parlous state, however my theory is GFC Mk II will not come from the US. There are countries in a far worse position than the US that I think will crumble well before they do. Japan, Italy, Spain, Greece and more importantly France are so far down the ‘debt hole’ that there is no coming back.

The ageing demographic in Japan is a real worry; lower tax revenues + higher entitlement spending is a no win equation for a country with public debt nudging 250% of GDP. 

The southern European states and France have an embedded socialist culture. Again, retiring boomers are going to test the elasticity in these countries’ welfare and healthcare budgets.

Based on nothing other than history my forecast is that the spark which sets fire to the global debt tinder is going to come from a source no one is really looking for. The surprise factor is what throws markets into a death spiral.

Expect the Unexpected

Look at the US share markets over the past few weeks leading up to the debt ceiling ‘crisis’. Yes, they were down a few hundred points. But nowhere near the 6,000+ point fall that accompanied GFC Mk 1.

This tells us the market was a little concerned but not overly worried. Everyone was looking in the direction of the debt ceiling ‘crisis’. It was not an unexpected ‘crisis’.

Ironically, the one we have to worry about is the one we don’t know about – as illustrated by former US Defence Secretary Donald Rumsfeld’s famous line about the ‘unknown unknowns,‘ which leads me to answer your question regarding the USD versus the AUD.

Here’s the important part:

IF (and that’s all I can go by is IF) the next financial crisis is sparked beyond the shores of the US, there will be a scramble to buy USD as investors rush to the perceived safety of US Treasuries. Yes these are the same Treasuries that up until last Wednesday may have been defaulted on – the markets are so fickle!

This is what happened in GFC Mk 1. Nearly every currency fell against the USD as money poured into the US Treasury market. At one stage, investors were buying negative yields just to have the security of a US Treasury Bond.

So while the US economy is rickety, there are others on a far less stable footing that I think will topple well before the US. The domino effect should see the USD strengthen significantly.

My assessment could be wrong. However, the odds of the US being the first to teeter are, in my opinion, low. The Fed can print money till the cows come home, whereas most other sovereigns (especially those with a history of default) are more likely to shirk their bond holders and in turn spark a rout in the bond market.

Time will tell but I am still comfortable with holding US dollars at this stage. The Reserve Bank of Australia will also want our dollar sub-90c to restore some competitiveness to our manufacturing industry. In fact, don’t be surprised if the RBA starts participating (via dollar selling) in the global currency war (the one no G20 official speaks about.)

The skittishness we have witnessed is all part of the theatre that accompanies the growing instability in the global post-GFC economy. Anyone with a passing interest in markets and the economy either consciously or subconsciously knows the system is being propped up rather than genuinely recovering.

Eventually something gives and I suspect it is going to be a left-field event. Waiting and watching for this debt drama to play out is never easy. Each day feels like a week. This is why patience (together with cash) is the greatest asset for prudent long-term investors.

Vern Gowdie+
Contributing Editor, Money Morning

Join Money Morning on Google+

Why Chen Lin Is Buying Fracking Stocks and Selling Gold Holdings

Source: Tom Armistead of The Energy Report (10/31/13)

http://www.theenergyreport.com/pub/na/why-chen-lin-is-buying-fracking-stocks-and-selling-gold-holdings

Chen Lin, author of What is Chen Buying? What Is Chen Selling?, goes wherever he sees returns. In the summer, he bought mining stocks when the yellow metal hit $1,200 per ounce. Now, he’s trading in his gold names and moving into the fracking space after a three-year hiatus. In this interview with The Energy Report, Lin names the companies he’s buying to play a likely energy sector bottom and tells investors to actively manage their portfolios in the coming stock-picker’s market.

The Energy Report: Chen, welcome. What is your take on the international prospects for drilling in 2014?

Chen Lin: Actually, the most exciting development for me is closer to home. I think the major action is in the U.S. and Canada. The whole fracking revolution is picking up steam. We could see as much as a 1 million barrel per day (1 MMbbl/d) increase in North American oil production! The United States is finally inching closer to energy independence, which could have a profound impact on the world.

TER: What are the catalysts that are going to move oil and gas in the coming year?

CL: Right now the key to watch is the Fed—if it’s going to taper, when it’s going to taper. This year I was betting the Fed would delay tapering. I think it probably will taper, at the latest, early next year. Fed action could have a very strong impact on the commodity space, for commodity prices as well as commodity stocks.

TER: How will these conditions affect the oil and gas companies in your portfolio?

CL: My portfolio in oil and gas is quite broad. I try to pick the stocks that can move on their own. They can move on their news, trading results, their success in certain areas. They won’t be affected too much by the Fed or by the commodity price. The tapering will actually have a negative impact on energy and stocks in general.

TER: How has your oil and gas portfolio been doing this year?

CL: The first half was very difficult for commodity stocks in general, not just energy. Mining of any kind was hit hard. Stocks just continued to go down without any reason. Then oil stocks started to scream back in the past month. I was very lucky this year because in the summer I was buying gold stocks. Then when gold hit $1,400 per ounce ($1,400/oz), I told my subscribers that I was planning to sell. I sold most of my gold stocks in late August/early September. I was just buying energy, and energy bottomed around that time, so many have already moved a lot in the past month.

TER: Are you expecting to add to your oil and gas portfolio or drop any companies?

CL: I’ve been adding energy plays lately. I also sold some of the energy plays, like Coastal Energy Co. (CEN:TSX.V), in which I had quite a large position. I reduced my position because it depreciated a lot. The next 6–12 months will probably be quite a tricky timeframe, so you have to actively manage your portfolio. I try to add and drop, get in and out of companies actively.

TER: In one of your letters you said you were buying fracking plays this year. Why weren’t you doing it earlier?

CL: Because they were very bad performers in the past three years. I sold fracking plays three years ago with a very good profit. At that time, fracking had just started and people were rushing into the space. I got out because I realized the capital costs are very high for a lot of companies. Issuing debt for a small company costs a lot of money.

Three years later, fast-forward, the fracking play companies have done so badly since then. Many are down as much as 90%. They are down so low that if the management chooses to sell all its land and the shale position, you can get a lot of backers at this current stock price, which means that the stock price was pressured very, very hard.

Meanwhile, Exxon Mobil Corp. (XOM:NYSE) is actively buying, and all the other major companies are moving into the fracking plays. There are a lot of deals going on. Also deals from China, from Korea, from Japan. Then the deals traded at a much higher premium to stock prices. Part of the reason I got into the fracking play is that it’s a good value proposition. There are not a lot of management teams that are not willing to sell in case of a takeover, for example, so that also could benefit shareholders. That’s why I got back into the fracking plays about one to two months ago.

TER: You say the fracking companies were doing poorly before. Were the oil companies doing any better than the average, or were oil and gas doing about equally poorly?

CL: The oil and gas companies were not doing well in the past two years in general, but the fracking plays were doing even worse. There were multiple reasons. West Texas Intermediate (WTI) was low, and the spread of WTI to Brent was very high, $20–25 sometimes. Companies were forced to sell at a price well below Brent. In order to continue drilling, they had to borrow money or issue shares. Even my recent best performer, Penn Virginia Corp. (PVA:NYSE), performed very poorly. It was a $30 stock in 2010. It went down all the way to $4/share this year. I bought it at $4.70, and it went over $7 in one month, which is good for me and my subscribers, but imagine a shareholder who bought at $30 in 2010. Same thing for my other best performers lately: Rock Energy Inc. (RE:TSX) was trading at $6 in early 2011; it dropped all the way to $1. I was fortunate to get in at ~$2 a couple of weeks ago; now it’s over $3. BNK Petroleum Inc. (BKX:TSX) was more extreme, trading at around $6 in early 2011, it dropped below $0.40 and is now close to $2. If BNK has any successes in Poland in a few months, I believe the stock can revisit the old high. You can see how volatile these stocks can be, and I was very fortunate to have sold my fracking stocks in late 2010 and early 2011.

TER: What has changed in the fracking plays to make them more attractive now?

CL: There a couple of reasons. The WTI/Brent spread has narrowed dramatically in the past six months. At one point, WTI/Brent was trading at par this year. That’s the first reason. Second, the fracking technology has improved. Most companies know how to drill a well cost-effectively and to get the most production out. As technological development is ongoing, a lot of questions have been answered. Infrastructure started building up. We see there are some pipelines at least in the lower part of United States already built up. Finally, large companies and Asian countries are starting to buy into the fracking play, paying as much as $60,000 per acre. That was a record.

TER: Are you still expecting a major decline in the price of oil?

CL: I’m concerned about the oil price. One of the reasons is that the production going on in the United States and Canada has tremendously increased. The annual production rate increased by nearly 1MMbbl/d between 2011 and 2012. The Middle East situation is starting to quiet down as well. Recently I heard Saudi Arabia has been cutting back to maintain the high oil price. It’s hard for me to imagine the country continuing to do that at its own expense.

TER: What draws your attention to a particular energy company, like Pan Orient Energy Corp. (POE:TSX.V) or Mart Resources Inc. (MMT:TSX.V), that motivates a buy decision?

CL: Companies I favor have their own unique stories; the companies can move on their own. They’re not dependent, for example, on the financial market. They don’t need to raise money. They’re going to have a very significant company-changing event potentially happening in the next 3–6 months. Those I believe can significantly move the stock price.

TER: Which companies on your scorecard have been doing their best work this year?

CL: If you look at the long-term performance, probably Mart was still my best performer. I got it at $0.15. I think I told my subscribers it would become one of my largest positions. It’s over a dollar now. Consider how much dividend that’s paid. You get all the money back if not more.

Mart is going to build its own pipeline for its Nigerian oil field because the current pipeline is poorly maintained, and the stock suffered because the pipeline loss recently was as high as 20–25%. People were concerned so much oil was stolen. However, when Mart builds its own pipeline, which the company expects to do in H1/14, then it can improve oil production and move to a much better maintained pipeline with much less loss. That will be a major catalyst.

Again, it’s a Nigerian company. A lot of people have doubts about a Nigerian company. Sometimes people need to see the pipelines built before investing in the stock. You need some patience. They’re paying about $0.20/ year dividend. I just received my recent quarterly dividend. You keep getting paid while waiting.

TER: Mart Resources’ production losses at the Umusadege oil field in Nigeria were much greater this year than last. It looks like it was because of longer and more frequent export pipeline shutdowns and oil theft. How would Mart make its new pipeline better protected?

CL: It will go through a completely different system. This is the other export route where losses are a small fraction of the AGIP pipeline.

It’s an old Royal Dutch Shell Plc (RDS.A:NYSE; RDS.B:NYSE) pipeline. At last report, Mart was only a few kilometers away from connecting.

If you look at the pipeline from this year and last year you will understand why the stock went down this year. Last year, the pipeline was running fine and Mart was doing fantastically. In the past two or three years Mart was the best performer among all energy stocks. This year the pipeline has had a lot of issues—flooding, theft. Mart shares were hit hard, though it was completely out of the company’s control. Hopefully when the new pipeline starts, the new route from the Shell exit facility, we will see a very different company. Then Mart will triple production, so you will see much larger production, more cash flow and potential increase of dividend, which is already very high. I think that dividend is 13–14% right now.

TER: Do you have a target expectation for Mart’s performance or stock price after the completion of that line?

CL: Right now I do not, but I expect the stock will be substantially higher than the current price because the company can triple production and the cash flow. The year 2014 could be a banner year for the company with huge cash flow coming in. The stock should be a multiple of the current price, but time will tell.

TER: Is religiously motivated violence in the northeast of Nigeria likely to affect Mart’s profitability?

CL: It’s possible. Nigeria is a risky place. As you said, the northeast part of the country, which is dominated by Muslims, has a lot of problems with violence against Christians. Fortunately, Mart is operating in the southwest part. It’s closer to the shore, in a relatively stable area, so they don’t have too much religious violence.

TER: In an interview with The Energy Report in January, you said that Pan Orient has the potential to be a tenbagger this year. How has it performed?

CL: It has not performed very well, certainly below my expectations. Part of it was that the big wells it’s trying to drill have not been very successful. Five big wells all turned out to be dry holes, which is very disappointing, but that’s the risk we take by investing in exploration companies. However, right now it’s entering a very interesting phase because Pan Orient’s neighbor just found a large oil pool just on the border of Batu Gajah (77% owner and operator). The crest part of the discovery—the best part—is on Pan Orient’s land. The discovery is rather large. It may be over 150 million barrels of oil equivalent (150 MMboe). It has oil, it has gas condensate and it has gas.

The discovery well was drilled only 175 meters from Pan Orient’s border. You can go to Pan Orient’s website and see the location of the well. You can see the crest of the discovery is right on the Pan Orient concession. That makes a very interesting play because you can drill right there and it becomes very low-risk drilling, because the other company drilled three wells. The first two wells averaged more than 6,000 boe. The third well they’re still testing. It’s right on the border. Pan Orient has the best part of that. This could be a very nice discovery.

My understanding is Pan Orient is going to partner out all three of the major Indonesian concessions. It expects to receive a large down payment and to have the partner carry out the next few wells on each concession. Since Pan Orient spent close to $100 million in all the drilling, the seismic, the groundwork, I expect it to get a lot of the money back from partnering. Potentially, it could be tens of millions. It’s very hard to give an exact number because it is negotiating with its partners right now.

Its cash position should substantially increase. I would guess it would be around $1.50 after everything’s over. Right now the stock is a little over $2/share. So the company will have around $1.50 in cash, then it has its partner(s) drilling the well—potentially I would say 8–10 wells in Indonesia at the partner’s cost. It has a big oil target coming up in Thailand that it’s going to drill. You can see the 3D seismic on the website. It’s a very large target. Over there in Thailand, it only costs $1–2 million to drill. Then it also is fully funded to do the heavy oil in Canada. The company has three possibilities, and all three have a very good chance to succeed. Success in each of them can dramatically change the stock price.

TER: Andora Energy has a steam-assisted gravity drainage project at Sawn Lake. When is that one going to produce its first oil?

CL: It’s going to start drilling in early October. First oil should be in Q1/14. Sometime in Q1/14, we will know the results of the well. Remember, the second largest French company, Maurel & Prom (MAU:EPA), is already Pan Orient’s partner there. The company subscribed a private placement at 1,200% premium to the stock price, which tells you how undervalued the whole area is.

TER: Can you talk about some other companies in your portfolio?

CL: I’m buying different energy plays. About the end of August/early September, my major additions were BNK Petroleum, Penn Virginia Corp., Ithaca Energy Inc. (IAE:TSX) and Harvest Natural Resources (HNR:NYSE). We had a very tough H1/13 on commodities. I was very lucky to buy gold miners during the summer, when gold was testing $1,200/oz. When it hit $1,400/oz, I was extra lucky to sell these gold miners to use the money to buy those energy stocks. That actually turned out to be a very good trade.

BNK is an interesting company. Its recent well results in the U.S. have been fantastic. It is surrounded by Exxon, and will likely sell the assets to Exxon, which it has done before. Then the company cash level should be around its market cap. It has about one million acres in Poland and will drill the first well in early 2014. If it is successful in Poland, the sky is the limit. Remember, BNK had a billion-dollar market cap just based on Poland in early 2011!

I already sold Penn Virginia; it jumped 70-80% for me in one month. Though I still believe there is value in the stock, I would wait for a pullback to buy it again. Ithaca Energy also moved up a lot, but it still has a lot of upside room. It’s a North Sea-based oil exploration company trading at 1–2 times cash flow. If the company can continue to execute, I think it still has substantial upside.

Harvest Natural Resources is a special play here. If you calculate the recently announced transaction, you will see the company can pay off all its debt and have $10/share cash left on its balance sheet, from which it intends to distribute around $6 to shareholders. The stock’s still trading around $5. Potentially you can get your money back plus you have another valuable spin off with very interesting asset in Indonesia and in Colombia plus $4 on the balance sheet for free. Most important, the company’s worth is independent of market fluctuations. That’s why I like it.

Rock Energy has been another great performer for me lately. It should have more upside left since the recent wells derisked the whole area. One interesting play is RMP Energy (RMP:TSX). Its recent well flows 2,000 barrels per day (2,000 b/d) oil. The payback of the well is less than one month, something unheard of in the fracking space. The company just consolidated the area and has around 100 drilling locations just on that property. They are planning to upgrade the oil processing facility to 20,000 b/d in Q1/14, when we will see a huge jump in production.

Recently I found a very interesting stock I’ve been accumulating. The company name is NXT Energy Solutions (SFD:TSX.V; NSFDF:OTCBB). It can fly airplanes over a field and detect if oil is present or not. It recently did a very large survey with PEMEX (Petróleos Mexicanos), the Mexican oil company. PEMEX already has seismic data on a certain field, they knew where it has oil deposits and where it doesn’t. PEMEX asked NXT to fly over, and the results were shockingly good. NXT found every large field for PEMEX! The report is on the website. PEMEX is the co-author.

If NXT can continue like this, it can change the oil industry as we know it. You probably need seismic later on to pinpoint where the oil is, but you can fly a plane over a very broad space and then detect where the oil is. That will be a revolution in the oil industry. It’s a very interesting company. It has a strong balance sheet. Recently it has started to go to the oil exploration companies and negotiate payment through royalties in exchange for its services. That can be a very interesting move. It’s an interesting company. I think if everything’s successful it has a very bright future.

TER: What is your outlook on energy in general for the next year?

CL: Like I said, I’m cautious about the oil price in 2014. The production from the U.S. and Canada is just amazing. If you read the Eagleford reports and Bakken reports you can see how many new wells are drilled. The completion techniques are getting better and deliver more oil production during the life of a well. I’m a little bit afraid the oil will fall much below $100/bbl. It’s possible.

On one hand, you have very high oil prices now. Most of my energy companies are making money. They’re doing fantastically. Though I’m not very confident the high oil price is here to stay. I want to remind everyone that if oil drops to below $80/bbl, the party of fracking stocks may be over. I would be careful and take profits as they go up. I’m going to watch the market month by month and see if the situation changes. I also believe that 2014 will be a stock pickers’ market. If you pick the right stock with the right catalyst, a stock can go up a lot just on its own. That’s what I’m looking at for 2014.

TER: Chen, thank you very much. This has been a fascinating conversation.

CL: Thank you. I appreciate it.

Chen Lin writes the popular stock newsletter What Is Chen Buying? What Is Chen Selling?, published and distributed by Taylor Hard Money Advisors Inc. While a doctoral candidate in aeronautical engineering at Princeton, Chen found his investment strategies were so profitable that he put his Ph.D. on the back burner. He employs a value-oriented approach and often demonstrates excellent market timing due to his exceptional technical analysis.

Want to read more Energy Report interviews like this? Sign up for our free e-newsletter, and you’ll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Streetwise Interviews page.

DISCLOSURE:

1) Tom Armistead conducted this interview for The Energy Report and provides services to The Energy Report as an independent contractor. He or his family owns shares of the following companies mentioned in this interview: None.

2) The following companies mentioned in the interview are sponsors of The Energy Report: Pan Orient Energy Corp., Royal Dutch Shell Plc and Mart Energy Resource Inc. Streetwise Reports does not accept stock in exchange for its services or as sponsorship payment.

3) Chen Lin: I or my family own shares of the following companies mentioned in this interview: Mart Resources Inc., Pan Orient Energy Corp., Ithaca Energy Inc., Penn Virginia Corp., Harvest Natural Resources, BNK Petroleum, Rock Energy, RMP Energy and NXT Energy Inc. I personally am or my family is paid by the following companies mentioned in this interview: None. My company has a financial relationship with the following companies mentioned in this interview: None. I was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are my own comments and opinions. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.

4) Interviews are edited for clarity. Streetwise Reports does not make editorial comments or change experts’ statements without their consent.

5) The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer.

6) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise.

Streetwise – The Energy Report is Copyright © 2013 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part.

Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.

Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section. Their sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.

Participating companies provide the logos used in The Energy Report. These logos are trademarks and are the property of the individual companies.

101 Second St., Suite 110

Petaluma, CA 94952

Tel.: (707) 981-8204

Fax: (707) 981-8998

Email: [email protected]

 

 

Top 5 Reasons You Should Trade Binary Options

If you are one of the people who look at various ways to make money online, you have probably read or heard about binary options trading. In case you haven’t heard, binary options trading has had many people flocking to reap the rewards. There are several reasons why binary trading is the method that is becoming more popular. Here are the top five reasons.

Binary trading is easy. It’s a very simple system to learn. This trading options is not near as complicated as some other markets. Even a beginner can figure it out and make it work for them. Ease of use is probably the most common reason people cannot wait to get started trading with binary options. More information can be obtained from a binary options broker.

This type of trading also includes time limits (or expirations). It goes quick. The outcome of your trade is determined within just a few moments. This is why many investors choose this because they don’t have to wait for days to find out the results. Either way it goes, the simplicity and quickness are appealing to traders from all walks of life.

Binary options also offer the ability to trade multiple expiriations as well as multiple products simultaneously. This is possible because it is for such a short period of time. This enables traders to participate in these multiple trades and possibly increase their chances of profitability. This is another very popular reason people choose to trade options.

Trading with binary options is also one of the least expensive ways to trade. You can generally get in for as low as five dollars.A trader can select various investment amounts as he determines his risk level. That’s another benefit that keeps people coming back for more. If they can invest a small amount and possibly win a larger amount, you can bet there are thousands of people who will take advantage of this.

Binary Options in MetaTrader 4 will allow traders to trade both binary options as well as forex simultaneously. Anyone who trades can also  trade CFDs and other products their broker offers.

Before anyone gets involved in binary trading options, it’s always best to use a demo account first. This will give you a chance to participate in real time trading activities without risk. You can test your ability and do so without losing money. Always choose the best options trading platform for the activities you will be doing. The internet is loaded with information about the various types of trading. Make sure you do your own research. Make sure you understand the risk and possible gain of trading before participating. A broker can also help you. Avoid the scams and always verify any information that you come across when advice is given regarding trading.

To learn more please visit www.clmforex.com

 

 

Podcast: Are We in a Stock Market Bubble?

By The Sizemore Letter

Listen to Charles discuss the outlook for inflation–using Japan as an example–and whether or not we’re in a stock market bubble with Mike Robertson on Straight Talk Money.

Charles and Mike consider arguments from InvestorPlace’s Jeff Reeves and Pension Partners’ Michael Gayed.

Related reading:

Reeves: “Why This Market High is Different

Gayed: “The Mother of All Fed Surprises

In a nutshell, Reeves argues that the metrics used to gauge the market’s valuation are dated and that too much emphasis is given to returns data that is too old to be useful.  Jeff also pokes holes in the belief that we are “due” for a correction of 10% or more.  Gayed counters that defensive sectors are leading–which is typical of the late stages of a bull market–and that more cyclical asset classes, such as small-cap equities, have struggled to make new highs.

This article first appeared on Sizemore Insights as Podcast: Are We in a Stock Market Bubble?

Join the Sizemore Investment Letter – Premium Edition

Egypt maintains rates, downside risks to limit inflation

By www.CentralBankNews.info     Egypt’s central bank held its benchmark overnight deposit rate steady at 8.75 percent, as expected, saying the current rates were appropriate as the downside risks to economic growth combined with the persistently negative output gap since 2011 would limit the upside risks to inflation.
    The Central Bank of Egypt (CBE), which cut rates in August and September, said the downside risk to global recovery stem from the challenges facing the euro area and softening growth in emerging markets and it would “not hesitate to adjust the key CBE rates to ensure price stability over the medium term.”
    The central bank raised its rates by 50 basis points in March, but then cut by a combined 100 points in the previous two months, resulting in a net reduction this year of 50 points.
    Egypt’s headline inflation rate rose to 10.15 percent in September from 9.74 percent in August, but some of the rise was due to the Haj season and the beginning of the school year.
    Inflation is projected to continue to be affected by seasonal events, such as the Eid festivities and the school year, but “upside risks to the inflation outlook continue to moderate as the possibility of a rebound in international food prices is unlikely in light of recent global developments,” CBE said.

    Egypt’s economy, hit by political unrest since the overthrow of former  President Hosni Mubarak in 2011, expanded by an annual rate of 1.5 percent in the second quarter, down from 2.2 percent in the first quarter.
    The CBE said investment levels remain low given the heightened uncertainty since early 2011 and the weak credit growth to the private sector.

    www.CentralBankNews.info

   
   

2013 Biotech Watchlist Update: Companies Climb and Crumble on Catalysts

Source: George S. Mack of The Life Sciences Report (10/31/13)

http://www.thelifesciencesreport.com/pub/na/2013-biotech-watchlist-update-companies-climb-and-crumble-on-catalysts

The Life Sciences Report‘s Biotech Watchlist, introduced in January 2013, is composed of 17 companies that industry analysts felt showed promise for the coming year—companies with productive pipelines, good management and stock-moving catalysts on the horizon. The new year presented legitimate prospects for portfolio growth and, indeed, that has been the case. In this update, we summarize the current status of Watchlist companies and introduce our Portfolio Tracker, showing the status of each company in real time.

A Quick Recap

Back in January our friends and collaborators at San Diego-based Sagient Research, publishers of theBiomedTracker, delineated important concepts about the market-moving data and events that can make or break smaller biotech companies. All stocks are affected by catalysts, but nowhere do they provide more leverage (positive or negative) than in the life of a biotech. And many of biotech’s key catalysts are tied to the regulatory process.

The Prescription Drug User Fee Act (PDUFA) is the most significant piece of legislation affecting the development path of a new drug. PDUFA was designed to speed up the drug approval process by having product sponsors pay the freight for U.S. Food and Drug Administration (FDA) staff that could rid the process of staggering bureaucratic delays. Review of new drug application (NDA) submissions is now promised in 12 months for standard submissions and eight months for priority reviews. There is also an emphasis on pre-submission meetings for NDAs and biologic license applications (BLAs), with the goal of making sure the applications are filed with minimal errors and can be expedited.

The FDA also allows drug developers to request that a product be designated as “breakthrough therapy,” with action on the breakthrough request promised no later than 60 days after submission. The first breakthrough designations came through in Q1/13 and included Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) cystic fibrosis drug Kalydeco (ivacaftor) (approved in January) and Pharmacyclics Inc.’s (PCYC:NASDAQ) ibrutinib, which is being developed in a lead indication for chronic lymphocytic leukemia (CLL) and has breakthrough therapy status for treatment of Waldenstrom’s macroglobulinemia and mantle cell lymphoma. Pharmacyclics is a Watchlist company.

Although therapies may still encounter jarring potholes on the road to FDA approval, 39 new molecular entities (NMEs) were approved in 2012, a 15-year high. Through Oct. 8, 2013, there have been 18 NMEs.

Choosing the Watchlist

Back in January, The Life Sciences Report asked a group of key biotech analysts to weigh in on their best ideas. The companies they identified included a number focused on the oncology space, with the rest targeting orphan diseases, immunotherapies, cardiovascular disease and diagnostic agents. The analysts were Mara Goldstein, senior biotechnology analyst at Cantor Fitzgerald; Raghuram “Ram” Selvaraju, managing director and head of healthcare equity research at Aegis Capital; John McCamant, editor of the Medical Technology Stock Letter; Mike King, senior analyst and managing director at JMP Securities; George Zavoico, senior biotechnology analyst at MLV & Co; and senior analyst Lisa Bayko of JMP Securities.

Of the 17 stocks on the Watchlist, 11 have posted gains ranging from 4% to 235%. The remainder has seen declines in stock value ranging from 3% to 85%. Though the doldrums of the last month—notably the government shutdown—have slowed biotech’s nearly two-year-long bull, the space is still bolstered by a stiff wind that originated in 2012. As of Oct. 21, the NASDAQ Biotechnology (NBI) index is up 44%.

Links to Previous Watchlist Updates and Stories

Biotech Watchlist Portfolio Tracker

How Are They Doing? Update on the Progress of Expert Picks

The Approval Process in Action (infographic)

January 2013 Biotech Watchlist

January 2013 Biotech Watchlist (story)

April 2013 Biotech Watchlist Update

April 2013 Biotech Watchlist Update (story)

PDUFA? What’s a PDUFA? Understanding the Drug Development Process Is Key to Biotech Investing

Company Updates

[Editor’s Note: All percentage increases or decreases in company stock prices are as of Oct. 21, 2013. All markets caps are as of Oct. 21, 2013.]

Amarin Corp. (AMRN:NASDAQ)

Back on Feb. 26, Amarin filed a supplemental new drug application (sNDA) for Vascepa (icosapent ethyl), its fish oil drug approved in July 2012 to lower triglycerides in patients with high triglycerides and mixed lipidemia, the drug’s ANCHOR indication. The FDA is scheduled to act on this application on Dec. 20; however, on Oct. 16, the agency’s Endocrinologic and Metabolic Drugs Advisory Committee met and voted 9–2 against approval. The FDA does not have to follow the panel’s advice, but investors hammered Amarin shares for a quite significant 60+% loss when trading resumed on Oct. 17. The company is down 72% year to date, and the stock is now back down in small-cap territory, with a $397M market value.

Ariad Pharmaceuticals Inc. (ARIA:NASDAQ)

It has been a tough year for Ariad. In mid-December 2012, the company got a surprise holiday gift when the FDA approved Iclusig (ponatinib) for two rare blood and bone marrow diseases, chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. It was a surprise because it came three months ahead of its scheduled PDUFA date, but investors sold on the news. . .and it has been all downhill from there. In early October of this year, news emerged that the FDA was scrutinizing Iclusig following increased reports of life-threatening blood clots and severe narrowing of arteries and veins. Although Iclusig is intended for patients who are no longer doing well with first-line therapies, the drug’s original label did warn about blood-clotting risks. On Oct. 18, Ariad announced that it was stopping its phase 3 EPIC trial of Iclusig in patients with newly diagnosed chronic myeloid leukemia. Ariad shares are down 85% YTD, and the market cap is down to $563M.

Celgene Corp. (CELG:NASDAQ)

Celgene is up 96%, with a $66B market cap. Analyst Mara Goldstein thoroughly explained why she recommended Celgene as a growth name, even though it was a large-cap stock at the time. For Goldstein this story was about the continuing development of a basket of products, including the multiple myeloma essential, Revlimid (lenalidomide), as well as Pomalyst (pomalidomide) also for myeloma, which was approved early February of this year.

There was also an sNDA being filed for an old chemotherapeutic agent formulated as Abraxane (paclitaxel protein-bound particles) for treatment of pancreatic cancer. Based on the company’s IMPACT study showing a clinically relevant increase in overall survival, Abraxane was approved by the FDA on Sept. 6 for use in combination with standard-of-care cytotoxic agent gemcitabine as the first new therapy sanctioned for metastatic adenocarcinoma of the pancreas in almost eight years. Celgene has also been developing apremilast for autoimmune disease indications, in particular rheumatoid arthritis and psoriatic arthritis. Investors have been anticipating phase 3 data that could come in H2/13. Celgene hasn’t disappointed; it has given investors a near double YTD.

Celldex Therapeutics (CLDX:NASDAQ)

Celldex is up 235%, with a market cap of $2.9B. Analyst Mara Goldstein got a near quadruple on Celldex, which grew up from small-cap to mid-cap company with its recent valuation. Celldex develops products that modulate the immune system; drugs in its pipeline target various cancers as well as other diseases.

Celsion Corp. (CLSN:NASDAQ)

In Q1/13, Celsion’s ThermoDox (liposome-encapsulated doxorubicin) suffered a letdown in its phase 3 HEAT trial for hepatocellular carcinoma (HCC), which resulted in a single-day drop in the company’s stock of 81%—a textbook case of a binary event affecting a one-product pipeline and causing shares to tumble dramatically. Year to date (YTD) the stock is down 85%. The company’s market cap is about $73 million ($73M).

Galena Biopharma Inc. (GALE:NASDAQ)

Galena is testing its immunotherapeutic product NeuVax (nelipepimut-S) in a phase 3 trial called PRESENT. The vaccine is intended to prevent recurrence of breast cancer in women with low to intermediate HER2 expression. Over the course of three years patients will receive a total of 11 immunizations; the primary endpoint will be disease-free survival.

There is also a phase 2b trial in progress with NeuVax in combination with Herceptin (trastuzumab), and a phase 1/2 study with Galena’s second targeted cancer immunization agent, folate binding protein (FBP) in ovarian and endometrial cancers. Results from the phase 1 study with FBP were announced in June at the American Society of Clinical Oncology (ASCO) annual meeting. Galena is up about 39% year to date, with a market cap of about $186M.

Hyperion Therapeutics Inc. (HPTX:NASDAQ)

Hyperion received approval for Ravicti (glycerol phenylbutyrate), for urea cycle disorders, on Feb. 1. Shares are up about 103% year to date, as product rollout continues. Hyperion’s market cap is about $463M.

Medivation Inc. (MDVN:NASDAQ)

On April 1 Medivation and partner Astellas Pharma Inc. (ALPMF:OTCPK) announced an updated interim analysis plan for the phase 3 PREVAIL trial of Xtandi (enzalutamide) in chemotherapy-naďve patients with metastatic castration-resistant prostate cancer. Still expected in 2013, these data could herald Xtandi as a best-in-class agent compared to Johnson & Johnson’s Zytiga (abiraterone acetate). The company’s stock price shot up on the catalyst, but has lost most of those gains since then. Medivation is down 3% YTD, and its market cap is about $3.9B.

Navidea Biopharmaceuticals Inc. (NAVB:NYSE)

Navidea received approval of its radiopharmaceutical diagnostic medium, Lymphoseek (technetium Tc 99m tilmanocept) on March 13. Lymphoseek is an isotope that is sensed intraoperatively by the surgical oncologist with a gamma detector and is approved to map the location of lymph nodes draining and disseminating metastatic disease from primary breast cancers and melanomas.

Hoping to expand into new disease indications, the company has been conducting a phase 3 study of Lymphoseek in head-and-neck cancers. The company hopes to file an sNDA for this indication before the end of 2013. While this story continues to hold together, the stock is down about 25% year to date. In the future, stock catalysts will include approval for new disease indications, uptake by surgeons and hospitals, and actual product revenues. Lymphoseek is marketed through Cardinal Health Inc. (CAH:NYSE), the largest sales channel for diagnostic isotopes in the U.S. Navidea’s market cap is about $259M.

NewLink Genetics Corp. (NLNK:NASDAQ.GM)

NewLink Genetics is developing algenpantucel-L for pancreatic cancer and tergenpumatucel-L for non-small cell lung cancer. Both are in phase 3 trials. Shares are up 45% YTD, and the company is now valued at about $442M.

Onyx Pharmaceuticals Inc. (ONXX:NASDAQ)

Onyx, an oncology franchise, experienced the drug developer’s dream-come-true when two of its drugs, Kyprolis (carfilzomib) for multiple myeloma and Stivarga (regorafenib) for metastatic colorectal cancer and gastrointestinal stromal tumor, moved to the market in 2012. The share price doubled last year, and was up about 61%, with a market cap of about $7 billion ($7B) by the time the company was acquired by Amgen Inc. on Oct. 1 for $658M.

Peregrine Pharmaceuticals Inc. (PPHM:NASDAQ)

Peregrine’s monoclonal antibody bavituximab, in development as a second-line therapy in non-small cell lung cancer (NSCLC), has rebounded following a labeling snafu that compromised its phase 2b study. A subsequent analysis of the study results showed a “meaningful but not statistically significant 4.4-month increase” in median overall survival (mOS), explained George Zavoico of MLV & Co. back in our April Watchlist update. After the company explained the situation to investors, shares popped 73%. Shares are up about 4% YTD.

In May, Peregrine announced that it had mapped out its pivotal phase 3 trial design for bavituximab in second-line NSCLC with the FDA. The study will be known as the SUNRISE trial and is expected to begin by year-end. Shares are up 4.48% YTD; the company’s market cap is about $217M.

Pharmacyclics Inc. (PCYC:NASDAQ)

Pharmacyclics’ ibrutinib (PCI-32765), a Bruton’s tyrosine kinase (BTK) inhibitor, has enjoyed tremendous success in clinical trials for patients with B-cell blood cancers, particularly chronic lymphocytic leukemia (CLL) and mantle cell lymphomas (MCL). In late August the company was told by the FDA that its NDA for ibrutinib had been accepted, which triggered a $75M milestone payment from development partner Janssen Biotech (a unit of Johnson & Johnson [JNJ:NYSE]). Investors are awaiting approval, which could come by the end of this year. The stock is up 107% YTD, and the market cap is about $9.5B.

Prana Biotechnology Ltd. (PBT:ASX)

Prana was another of Zavoico’s Watchlist picks. He called it one of the biggest risk/reward opportunities of this year, citing its investigational drug PBT2, which has restored cognition in mouse models of Alzheimer’s disease (AD). PBT2 is currently in a phase 2b trial for AD and in phase 2a for Huntington’s disease. Zavoico called Prana’s focus on the role played by biological metals in the development of degenerative diseases such as Alzheimer’s and Huntington’s “a potential game-changer,” and cited the therapy’s novel approach as fitting with an FDA emphasis on finding “innovative approaches” that could benefit cognitive function for patients. The stock is up about 69% YTD, but has been volatile, due in part to its micro-cap status with a $152M market valuation.

Sangamo BioSciences Inc. (SGMO:NASDAQ)

Sangamo is developing DNA-binding proteins to regulate genes. The stock is up 74%; the company is conducting a phase 2 study of SB-728-T, which it believes may be a “functional cure” for HIV/AIDS.

In early March Sangamo presented data from its phase 1 study showing that a single treatment with SB-728-T produces a “durable reconstitution of the immune system” by expanding memory CD4+ T-cells, which have the capacity to recall and then rapidly respond against HIV and other foreign antigens. With personalized medicine and associated biomarkers gaining credibility with regulators, data from this study also demonstrated that specific cell surface markers, as well as gene expression characteristics, might predict which patients would be most responsive to the therapy. More than 33M people globally have HIV and AIDS, with an estimated 1.2M in the U.S. Sangamo’s market cap is about $575M.

Sarepta Therapeutics Inc. (SRPT:NASDAQ)

Sarepta is up about 58% YTD, but that pales next to last year’s 481% rise. Sarepta is an antisense drug development company working on a true disease-modifying therapy for Duchenne muscular dystrophy (DMD). Normally a patient with DMD, considered an orphan indication, becomes incapable of walking between the ages of seven and 13, and may not live beyond the second or third decade of life.

At the beginning of April, the company put out top-line data on its exon-skipping drug eteplirsen (AVI-4658) in a phase 2b study that showed a “sustained benefit” in patients. Eteplirsen modifies protein synthesis from DNA to skip exon 51 of the dystrophin gene, making the resulting dystrophin protein shorter but still serviceable. It’s a structural and functional repair that can slow, or perhaps prevent, muscle breakdown. In September, the company announced that study results at 96 weeks “showed a continued stabilization of walking ability in eteplirsen-treated patients.” Sarepta’s current market value is in the $1.4B range. If eteplirsen gains acceptance and ultimate approval, the stage is set for a leap in Sarepta’s share price.

Trius Therapeutics Inc. (TSRX:NASDAQ)

Trius delivered good news on March 25 when it released data from its phase 3 ESTABLISH 2 trial with tedizolid phosphate for acute bacterial skin and skin structure infections. The study met its primary endpoints, determined by both the FDA and the European Medicines Agency, as well as all secondary efficacy endpoints. Trius was acquired by Cubist Pharmaceuticals Inc. in September for $658M, giving investors a 185% return from the start of 2013.

Want to read more Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you’ll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Streetwise Interviews page.

DISCLOSURE:

1) Author George S. Mack provides services to The Life Sciences Report as an independent contractor. He or his family own shares of the following companies mentioned in this article: None.

2) The following companies mentioned in the interview are sponsors of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services.

3) Interviews are edited for clarity. Streetwise Reports does not make editorial comments or change experts’ statements without their consent.

4) The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise.

Streetwise – The Life Sciences Report is Copyright © 2013 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part..

Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.

Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section. Their sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.

Participating companies provide the logos used in The Life Sciences Report. These logos are trademarks and are the property of the individual companies.

101 Second St., Suite 110

Petaluma, CA 94952

Tel.: (707) 981-8204

Fax: (707) 981-8998

Email: [email protected]

 

 

The Fed’s Gameplan on Straight Talk Money

By The Sizemore Letter

I joined Mike Robertson this morning to discuss the Fed’s announcement and what it means for tapering, inflation, and the stock market on Straight Talk Money.  You can listen to the audio in the embedded player above.

So, what should we expect?  What is the Fed’s gameplan?

Bernanke wanted to close the door on quantitative easing before leaving office in January.  That’s not going to happen.  Weaker than hoped-for growth and the fallout from the government shutdown make tapering on Bernanke’s original timeline a nonstarter.  Expect the current policy regime to last well into the first quarter of 2014…and possibly longer.

This article first appeared on Sizemore Insights as The Fed’s Gameplan on Straight Talk Money

Join the Sizemore Investment Letter – Premium Edition

Fiji holds rate steady, revises up growth forecasts

By www.CentralBankNews.info     Fiji’s central bank maintained its overnight policy rate (OPR) at 0.5 percent, unchanged since December 2011, and revised upward its forecast for economic growth this year and next year.
    The Reserve Bank of Fiji forecast growth of 3.6 percent this year, up from August’s forecast of 3.2 percent, and 2014 growth of 3.0 percent, up from an earlier 2.5 percent forecast. Fiji’s economy expanded by 2.2 percent in 2012 and the International Monetary Fund forecasts 3.0 percent this year.
    Despite this upward revisions, Reserve Bank Governor Barry Whiteside said the economy still needed support in light of the IMF’s downward revision of its global growth forecasts and the bank’s policy stance was maintained “given the comfortable outlook for the Reserve Bank’s twin objectives (low inflation and comfortable foreign reserves).”
    Fiji’s inflation rate rose to 3.1 percent in September from 2.5 percent the previous month, but the central bank still projects year-end inflation of 3.0 percent due “subdued global demand conditions and contained food and energy prices.”
    Fiji’s trade deficit widened due to higher imports and a slow recovery in exports, but the Reserve Bank said higher tourism earnings, remittances and inward investments supported the balance of payments’ position with foreign reserves “comfortable” at $1.783 billion, sufficient for 4.9 months of imports, slightly down from around $1.834 billion at the end of August.

    www.CentralBankNews.info

Gissen and Berol’s Gold Stock Tricks and Treats

Source: Brian Sylvester of The Gold Report (10/30/13)

http://www.theaureport.com/pub/na/gissen-and-berols-gold-stock-tricks-and-treats

No matter how elaborate an investor’s Halloween costume is, the gold space isn’t handing out much in the way of treats this year. While Encompass Fund Managers Malcolm Gissen and Marshall Berol don’t agree on the timeline for gold’s recovery, they have faith that it will come. In the meantime, their focus is on companies that are in production, generate cash flow and have top-notch management teams. They also dig into their treat bag for names in the energy sector and other metals in this interview with The Gold Report.

The Gold Report: It’s almost Halloween and we remain in the clutches of a tricky market for junior resource equities. What are your perspectives on how long it’s going to take before investors see another treat-filled year like 2010?

Malcolm Gissen: The last couple of years have been frightening for investors, in both gold commodities and gold stocks. Gold prices have been rising the last few weeks, allowing some people hope, but I don’t expect an appreciable change in the gold price and the appeal of gold mining companies until 2015.

Marshall Berol: I’m more optimistic than Malcolm. I think the market will change, possibly in as little as five months. The underlying fundamentals that have driven gold up over the last dozen years are still in place: the money printing presses, supply and demand for bullion, bars and coins. Costs are going up, so is the need for higher prices.

I would like to see the market refocus on fundamentals and get away from tracking the hour-to-hour and day-to-day activities of the financial players. What they are doing in the futures markets is driving the price of gold and other commodities up and down incessantly. The dollar is up; the dollar is down. Oil is up, oil is down. Stock prices react to whatever news is coming out of Washington, Europe or Japan. At some point, investors will realize that gold’s underlying fundamentals have not changed and that there are reasons to buy it.

MG: We started investing heavily in gold in the accounts of clients of our RIA firm, Malcolm H. Gissen & Associates, in 2002, when gold was under $300 per ounce ($330/oz). We built allocations to precious metals of 15ñ18% by 2004. When Marshall and I launched the Encompass Fund in mid-2006, gold companies was the largest asset class. We believed that gold was deeply undervalued and with India and China, cultures that value gold and use it as a currency substitute, developing a middle and upper class, demand for gold would increase exponentially. We also knew that many investors would come to realize that the gold price would go up because of inflation and currency devaluationóthe historical reasons people buy gold.

That attitude has changed over the last two-and-a-half years. Fundamentals no longer seem to play a role in attracting investors to buy gold or gold stocks. Marshall thinks it would be nice for people to go back to looking at fundamentals; I’m not sure that will happen. The information explosionógossip, rumors and trying to guess what hedge funds and private equity investors are doingóplays an increasingly larger role in decision-making.

One factor that would cause gold to rise would be the realization that the U.S. government is printing money to deal with its tremendous debt. This is not sound policy. This should scare people, but it doesn’t seem to at this time.

The Federal Reserve is doing everything it can to keep interest rates low, which is good for corporations and good for the economy, but it is doing that by buying bonds and mortgages. Eventually, we will have to pay the piper. At that point, hard assets like gold and silver will look a lot more attractive. Until we get to that point, I’m concerned that gold will not break out of the range it has been trading in for the last couple of years.

TGR: Change will require the onset of fear.

MG: Fear is definitely one strong motivator. Unlike Halloween, where children (and many adults!) love going to haunted houses to be frightened, people do not seek fear in their investments. Rather, they avoid fear, often at all costs. If fear returns in the markets, Marshall and I think that gold is likely to be a place where investors will move their money.

Another new development affecting gold and silver prices in the long run could be supply constraints. The world’s largest mining companies have realized that they must be more sensitive to escalating costs of building and operating mines, especially with gold and silver at present prices. They can’t rely on $1,600ñ1,900/oz gold prices to pay for $3ñ7 billion ($3ñ7B) expansion and construction projects and remain profitable. With gold in the $1,000ñ1,300/oz range, some companies are not profitable.

I just attended an excellent presentation by Juan Carlos Artigas, head of investment research at the World Gold Council. While arguing that all investors should have a 3ñ10% allocation to gold because it is an asset with low correlation to almost all other assets, he pointed out that all-in costs for some gold producers were in the $1,200/oz range. As a result, CEOs are less willing to build large projects. We also have seen much less merger and acquisition activity among the majors. I believe that will, over the next few years, threaten the gold and silver supply.

If gold supplies are threatened, it could raise gold prices. I can’t say whether that will happen in six months or three years, but I believe that we’re headed in that direction.

TGR: Do you expect the trend of up-and-down gold prices with no real pattern and with little consensus to continue until there is a decided move upward?

MB: Although we disagree on timing, we agree that gold will continue trading in the $1,200ñ1,450/oz range until it breaks out to the upside.

MG: I think there’s a floor in the $1,100ñ1,200/oz range. When gold goes below a certain level, companies will stop producing, there will not be enough gold to meet demand and we’ll see higher prices.

Industry executives tell us that if gold should ever get to $1,000 or $900/oz, they expect many of their colleagues to go on care and maintenance, because they can’t make any money at that price. They’ll go to a skeletal crew and cut back on production.

MB: It’s happening. Goldcorp Inc. (G:TSX; GG:NYSE) reported it is delaying work in Argentina due to rising costs and other factors. Its all-in sustaining cost is likely to be $1,050ñ1,100/oz for 2013. At that levelóand this is one of the largest gold miners in the worldómanagement teams cannot continue to produce and lose money.

TGR: Let’s look at silver. New York’s CPM Group expects silver prices to consolidate for another three years, at an average of $18/oz. Do you support that forecast?

MG: I don’t, for a couple of reasons. First, it’s very difficult to make forecasts for a specific timeframe. I cannot predict what will happen in three years. It is difficult enough trying to forecast where prices will be in three or six months! Second, because silver has so many more industrial uses than gold, I don’t see silver prices declining by an additional 15% after the sharp decline of the past year. I also do not believe that silver prices will break out until factorsósimilar to what I mentioned for goldóchange.

MB: Silver’s current price is $21ñ22/oz, so CPM’s forecast implies that the price will decline over the next three years. I don’t agree. About half of silver usage is industrialóelectronics and medical, for exampleóall of which are increasing.

Silver tracks the price of gold investment-wise, but I think it could do better than gold percentage-wise over three years. Historically, silver has been more volatile than gold. It goes up or down to a greater percentage than gold.

TGR: Malcolm, we’re just a couple of weeks beyond the federal government shutdown in the U.S. What are your thoughts on the long-term health of the American economy and the American political system?

MG: I’m going to stay away from the politics, because my politics and Marshall’s politics are almost diametrically opposite.

I believe the U.S. economy is much healthier than a lot of Americans realize. Our entrepreneurial spirit is extraordinary; the number of young people starting companies has never been greater.

Sometimes government can get in the way. We need more reasonable, workable regulation than we have now. If we do that, the sky is the limit for the U.S. economy. I don’t think that will change for many years; I’m very bullish on our economy.

TGR: In 25 years, will the U.S. greenback still be the world’s reserve currency?

MG: I think it will. Twenty-five years would be too soon for the American dollar to lose its position as the world’s basic currency, just as English is the dominant language used around the world.

MB: You also have to ask yourself what the reserve currency would change to. The euro isn’t in any position to become a reserve currency. Nor will it be the yen, the ruble or the peso. It may one day be the Chinese currency, but not that soon.

That brings us back to gold. It would not replace the dollar, but central banks are adding gold to their reserves to lessen the impact of the dollar on the percentages held in their reserves.

TGR: Did you make changes to your Encompass Fund (ENCPX:NASDAQ) due to the government shutdown?

MG: We made no changes in either client accounts or in the Encompass Fund. However, we did debate whether to move more to cash in the eventuality of a default on the U.S. debt and the negative impact that would have on the market. We concluded Congress would likely go right to the wire, when the more moderate Republicans would prevail and strike a deal.

MB: The client accounts are managed to each client’s individual goals and objectives. The objective of the Encompass Fund is long-term capital appreciation. We are not a trading fund. The turnover rate for the Encompass Fund runs around 25%. We don’t focus on day-to-day, week-to-week or even month-to-month news developments. We look for industries and companies that will do well over time.

TGR: What are your clients telling you these days?

MG: I think clients like less risk and less volatility, and we have moved in that direction over the last 12ñ15 months. We have invested client accounts in more large-cap, domestic stocks. We like the energy, healthcare and technology sectors. We also have added Real Estate Investment Trusts.

We’ve done the same thing in the Encompass Fund. It was more heavily invested in resource companies, particularly metals. Over the last six months, we’ve kept the best of the resource companies, but energy is now the largest component represented in the Encompass Fund.

TGR: Your website describes the Encompass Fund as a “go anywhere fund.” Geographically, where has the fund gone in the last year that it had not gone previously?

MB: It’s more a factor of where we’ve pulled back than where we’ve gone for the first time. The fund has a number of resource sector investments in Canada, the U.S., Mexico, South America, Africa and a couple of companies in Europe. We are more wary of jurisdictions that have experienced geopolitical problems, such as Argentina, Bolivia, Ecuador, areas where the governments appear less friendly toward resource operations.

TGR: Marshall, you’ve invested in resource companies based, in part, on your relationships with company management. How has the downturn in the junior resource space changed those relationships?

MB: It hasn’t changed the relationships as much as it has focused us even more on company management.

At the end of 2008, we assessed where all of the companies in the Encompass Fund were relative to their projects, finances and management. We reduced or eliminated a number of the companies that were not making the progress we had hoped for and added to those we thought were stronger. That worked out extremely well for the following couple of years, as the markets improved and some of the companies did likewise.

We did the same thing earlier this year, focusing even more on the management teams. In this very difficult environment, strong, knowledgeable managements with successful track records for bringing projects along and raising money are extremely important.

TGR: But you must have to say no to people when they come to you for more financing.

MB: Yes, almost every day. This year in particular, companies have needed to raise funds just to keep the lights on, much less advance their projects.

We are being far more selective in what we believe justifies funding. Primarily, that translates to companies that are in production and need funding to increase production, or are very, very near production.

TGR: Do the relationships just dry up when you have to turn down funding requests?

MB: I hope not. It’s a business decision. Companies are in a position where they need to ask. We’re in a position where we can and will say no if it doesn’t fit our portfolio objectives. I would hope that the management teams understand our position and our responsibility to our investors.

TGR: What is your current investment thesis for junior mining companies? What do companies you invest in today have to have?

MB: It’s very good if they’re in production or very near production. That means they’re generating revenue and cash flow of some kind and are advancing their projects.

Management and the state of the balance sheet are also factors. Companies with significant cash on their balance sheets are a lot more attractive.

With rare exceptions, it is difficult for us to justify investing in very early-stage companies in this environment.

TGR: This year investors have gotten more tricks than treats in the gold space. What are those rare treats that you’re following?

MB: We found a number of treats among the energy companies. We’ve been invested in Magnum Hunter Resources Corp. (MHR:NYSE.MKT) for some time. It’s expanding its operations in the U.S., primarily in oil, some in gas.

TGR: It was up almost 9% on Oct. 24.

MB: Yes. Many of the smaller companies are volatile. Magnum Hunter has doubled in price over the last couple of months. Thus, it’s more difficult to buy at these levels. A short while ago, we trimmed the position simply for portfolio management purposes; we still like the company.

We also find industrial metals, such as vanadium and antimony, attractive.

TGR: Which vanadium or antimony plays do you like?

MB: U.S. Antimony Corp. (UAMY:OTCBB) is expanding production in Mexico: mining, milling and processing. A number of strategic metals are currently sourced primarily out of China, and there are a lot of reasons why the users and governments around the world want to move away from China being basically a sole source supplier.

We have an interest in American Vanadium Corp. (AVC:TSX.V). While its project in Nevada is still a ways off, it also has a relationship with a German manufacturer of fuel cells used for energy storage for solar and wind power. That’s a very attractive business opportunity for American Vanadium to produce revenues in the short term while it moves ahead on starting production at its vanadium project.

TGR: Is that an offtake deal?

MB: It will be partially an offtake deal when it gets into production. Right now, American Vanadium is a sales agent for these vanadium-based batteries used to store energy produced by the solar and wind industries.

TGR: Returning to gold, which small-cap gold companies in the Encompass Fund portfolio would you like to talk about?

MB: Relative to a good management team able to move the company ahead and raise funds, I would mention Brazil Resources Inc. (BRI:TSX.V; BRIZF:OTCQX). It isn’t yet in production, but it recently announced acquisition of another Brazilian gold company. Marketwise, it has done better as a nonproducing junior company stock than many of its peers.

TGR: Earlier you talked about avoiding places like Argentina, Bolivia and Ecuador. Brazil is right in that neighborhood. Why are you comfortable investing in Brazil?

MB: The Brazilian government seems to be more reasonable, and it is a far larger and broader based economy than elsewhere in South America. Argentina, for example, nationalized a Spanish oil company and changed the tax laws, and the monetary situation is challenging.

TGR: Keeping with our trick-or-treat theme, which gold companies were tricky in 2013?

MB: There were a few whose stock prices suffered dramatically and that may be in positions to treat investors well in 2014.

One is Northern Dynasty Minerals Ltd. (NDM:TSX; NAK:NYSE.MKT). Its Pebble project in Alaska is very large and has a lot of gold and other metals. However, it is controversial from an environmental standpoint. Until mid-September, Northern Dynasty had Anglo American Plc (AAUK:NASDAQ) as its 50/50 partner. Then, Anglo American announced that it was withdrawing from the partnership and discontinuing its involvement, after having spent $541 million ($541M) of a projected $1.5B investment to develop the Pebble project. That took the Northern Dynasty price down dramatically, and it has basically stayed there.

Northern Dynasty says the advantage is that it now owns 100% of Pebble. Rio Tinto Plc (RIO:NYSE; RIO:ASX; RIO:LSE; RTPPF:OTCPK) owns 18% of Northern Dynasty. Nobody knows what will happen there.

TGR: Does CEO Ron Thiesssen need another partner to make a go of it?

MB: Yes, although Northern Dynasty claims to have the financial capacity to move forward with permitting and the project.

But investors were tricked, to use our Halloween analogy, because they thought Anglo would be putting another $1B into Pebble. Anglo’s announcement changed the project and the perception of Northern Dynasty. If these concerns can be straightened out, a year from now Northern Dynasty stock should be a real treat for those who invested at this level.

Another situation where the market got tricked is Pretium Resources Inc. (PVG:TSX; PVG:NYSE). Pretium has a major gold project in British Columbia. Its Valley of the Kings project is very high grade and very large. It was forecast to be in production in 2016. Earlier this month Strathcona Mineral Services Ltd., one of the two independent consulting firms working on a bulk sample project to delineate the gold resource, resigned. The stock took a hit.

Within the past week, Pretium released more details about why the firm withdrew. That raised even more questions about the nature of the project and how viable it is. The stock took another hit. The market felt tricked by an unexpected event driving the stock price down considerably.

If the consulting firm’s withdrawal and the reasons for it turn out to be a tempest in a teapot, Pretium stock will become a real treat for investors over the next few months and into 2014.

TGR: Do you consider Strathcona’s resignation an entry point to the stock?

MB: Not necessarily an entry point, but it creates what could be an excellent opportunity to get into the stock at half the price it was a month ago.

TGR: Snowden, another geological consulting firm, continues to oversee the bulk sample. Is having Snowden alone sign off on the bulk sample enough?

MB: It will be enough for some people, not for others. That is the conundrum in assessing Pretium and determining a good entry point price.

Some people will say there’s too much smoke and don’t want to get near it. Others will assess the situation as it develops and as the bulk sample results come outóPretium has announced results from about one-quarter of the 10,000-ton bulk studyóand will decide they want to invest.

TGR: Any other names you’d like to mention?

MB: We like Primero Mining Corp. (PPP:NYSE; P:TSX), which is making good progress at its San Dimas mine and Cerro del Gallo project in Mexico. It is producing cash flow, is growing and expanding and has a very accomplished, experienced management team. Despite recent questions about Mexico instituting a new tax and royalty structure, Mexico remains an attractive mining jurisdiction.

I recently visited Comstock Mining Inc. (LODE:NYSE.MKT). It has put together a major land package in the Comstock Lode area south of Virginia City, Nevada. It has been in production for about one year, and projects doubling its production to 40,000 oz gold equivalent in 2014, from 20,000 oz gold equivalent in 2013. The key for Comstock will be continued production expansion, which should lead to a lower cost of production per ounce and increased cash flow and operating margins. Increased exploration, which is ongoing, is likely to increase production and cash flow over time.

TGR: What tricks should investors avoid in today’s economic environment?

MB: Unfortunately, tricks are most noticeable with hindsight. I think the trick to success is to avoid assuming that when gold or silver prices rise that it will raise all the boats. While we remain optimistic on the price of gold and silver, just having an inexpensive stock doesn’t mean it will go up if the price of gold goes up. You have to dig deeper and look at the management, the projects, the location and the finances.

TGR: Indeed. That trick is a real treat. Thanks for your time and insights.

Malcolm Gissen founded Malcolm H. Gissen & Associates Inc., an investment advisory services firm, in 1985. His management experience has focused primarily on investments in publicly traded companies. He holds a Bachelor of Science degree from Case Western Reserve University and a Juris Doctor (J.D.) degree from the University of Wisconsin.

Since 2000, Marshall Berol has been the chief investment officer of Malcolm H. Gissen & Associates Inc. In addition, for more than 20 years, he has owned the investment firm BL/SH Financial. His investment management experience has focused primarily on investments in publicly traded companies. Berol did his undergraduate work at the University of California at Berkeley, and has a Juris Doctor (J.D.) degree from the University of San Francisco School of Law. Prior to entering the financial services industry, Berol was a partner in a San Francisco law firm.

Want to read more Gold Report interviews like this? Sign up for our free e-newsletter, and you’ll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Interviews page.

DISCLOSURE:

1) Brian Sylvester conducted this interview for The Gold Report and provides services to The Gold Report as an independent contractor. He or his family own shares of the following companies mentioned in this interview: None.

2) The following companies mentioned in the interview are sponsors of The Gold Report: Brazil Resources Inc., Pretium Resources Inc., Primero Mining Corp. and Comstock Mining Inc. Goldcorp Inc. is not associated with The Gold Report. Streetwise Reports does not accept stock in exchange for its services or as sponsorship payment.

3) Malcolm Gissen: I or my family own shares of the following companies mentioned in this interview: Magnum Hunter Resources Corp., U.S. Antimony Corp., American Vanadium Corp., Brazil Resources Inc., Primero Mining Corp., Comstock Mining Inc. and Encompass Fund. I personally am or my family is paid by the following companies mentioned in this interview: None. My company has a financial relationship with the following companies mentioned in this interview: None. I was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are my own comments and opinions. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.

4) Marshall Berol: I or my family own shares of the following companies mentioned in this interview: U.S. Antimony Corp., American Vanadium Corp., Brazil Resources Inc., Comstock Mining Inc. and Encompass Fund. I personally am or my family is paid by the following companies mentioned in this interview: None. My company has a financial relationship with the following companies mentioned in this interview: None. I was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are my own comments and opinions. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.

5) Encompass Fund (co-managed by Mr. Gissen and Mr. Berol) is invested in Magnum Hunter Resources Corp., U.S. Antimony Corp., American Vanadium Corp., Brazil Resources Inc. and Comstock Mining Inc.

6) Interviews are edited for clarity. Streetwise Reports does not make editorial comments or change experts’ statements without their consent.

7) The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer.

8) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise.

Streetwise – The Gold Report is Copyright © 2013 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part.

Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.

Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section. Their sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.

Participating companies provide the logos used in The Gold Report. These logos are trademarks and are the property of the individual companies.

101 Second St., Suite 110

Petaluma, CA 94952

Tel.: (707) 981-8999

Fax: (707) 981-8998

Email: [email protected]

 

“Distorting” US Policy Goes On, But Gold Falls After Fed, Silver Drops $1

London Gold Market Report
from Adrian Ash
BullionVault
Thurs 31 Oct 09:25 EST

WHOLESALE prices of gold and silver extended yesterday’s sharp falls in London trade Thursday morning, as world stockmarkets also fell following the US Federal Reserve’s latest policy statement.

Changing neither the US Dollar’s zero interest rate or $85 billion of monthly asset purchases, “Fiscal policy is restraining economic growth…Inflation has been running below the Committee’s longer-run objective,” the central bank said Wednesday.

 Deciding “to await more evidence that progress will be sustained before adjusting the pace of purchases,” the US central bank – which had flagged September as the likely start of ‘QE tapering‘ in June – said again that “a highly accommodative stance of monetary policy will remain appropriate for a considerable time after the asset purchase program ends and the economic recovery strengthens.”

 By lunchtime in London today, gold stood almost 3% below Monday’s 5-week highs, hitting the lowest price since last Tuesday at $1323 per ounce.

 Silver briefly dipped below $22 per ounce after breaking above $23 on Wednesday for the first time in 6 weeks.

 The rising Dollar knocked the Euro currency back to its lowest level in 2 weeks at $1.3625.

 Crude oil led commodities lower with a 0.5% drop. US government bonds rose in price, nudging the 10-year yield back down to 2.50%.

 “Clearly,” says today’s precious metals comment from German bank Commerzbank, “some market players expect the Federal Reserve to scale back its bond purchases in the near future.

 “[But] the Fed made virtually no changes to its statement that would justify this expectation.”

 Looking ahead, “The Fed will likely not do anything at its year-end meeting given that there are key budget and debt ceiling dates just a few weeks after that,” says Edward Meir at brokers INTL FCStone.

 “We think gold may be under pressure for the balance of the week, but the [precious metals] complex should regroup and push higher going into year-end.”

 Meantime, says ANZ Bank’s daily note, “Gold along with other markets, was positioned for a dovish Fed. With this event risk now behind us, the market will go back into data-watch mode.”

 Looking at gold market dynamics, “The slowing of physical demand and decline in Shanghai premiums will mean prices have to fall further,” says ANZ, “before sparking any strong end-user demand.”

 Shanghai gold ended Thursday equal to $1337.29 – some $1.50 above London spot gold per ounce – after dropping Tuesday to a discount to the world’s pricing benchmark for the first time in 2013.

 Declining trade volumes on the Tokyo gold futures exchange saw foreign traders account for a record-large 42% of the market in September, the Tocom said last week.

 Today the Bank of Japan stuck with its 0.1% interest rate and $700 billion per year of quantitative easing.

 “The recovery and the economy are distorted,” said a letter to clients this week from the $23 billion hedge fund Elliott Management.

 That makes the situation “uniquely positive for gold,” says the fund, run by prominent Republican backer Paul Singer, also saying Eurozone politicians have done nothing to fix the currency union’s “unsustainable structure”.

 Studying charts of the gold price, “If a picture can tell a thousand words, this does it quite succinctly,” says MacNeil Curry, head of global technical strategy at Bank of America Merrill Lynch, pointing to a monthly log chart of Dollar gold since 1980.

 Curry’s uptrend – which joins the rising price of gold’s lows of the early 2000s – is extended to 2013, but comes beneath and does not touch the market price since 2005.

 “There has been no damage to [gold’s] long-term uptrend which began back at the turn of the century,” says the BAML technician.

 Shorter-term, “I would certainly look for a move upwards of at least $100 from current levels.”

 Latest data from US regulator the CFTC – now 2 weeks behind with its Commitment of Traders report after the US government shutdown ended – meantime show speculators in New York gold futures cutting their net betting on higher prices by 25% in the week-ending Tues 15 Oct.

 Gold fell over 5% that week to hit a 3-month low of $1252 per ounce.

Adrian Ash

BullionVault

Gold price chart, no delay | Buy gold online

 

Adrian Ash is head of research at BullionVault, the secure, low-cost gold and silver market for private investors online, where you can fully allocated bullion already vaulted in your choice of London, New York, Singapore, Toronto or Zurich for just 0.5% commission.

 

(c) BullionVault 2013

Please Note: This article is to inform your thinking, not lead it. Only you can decide the best place for your money, and any decision you make will put your money at risk. Information or data included here may have already been overtaken by events – and must be verified elsewhere – should you choose to act on it.